Epicrispr Biotechnologies has completed enrolment and dose escalation in the first-in-human trial of EPI-321, an epigenetic CRISPR-based therapy for...

The latest clinical update includes dosing announcements for two trials, with the first patients now treated with Epicrispr Biotechnologies’ EPI-321...

Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...